Cognex's Strong Q2 Margins, Q3 Guidance Boost Shares, UBS Says

MT Newswires Live

Aug 01

Cognex (CGNX) posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.

The company's shares jumped 21% in recent Thursday trading.

The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance "firmly above" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.

Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.

UBS has a buy rating on Cognex stock with a price target of $53.

Price: 40.75, Change: +6.99, Percent Change: +20.70

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556371868"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556371868\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556371868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 00:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556371868","market":"us","top_or_hot":-1,"title":"Cognex's Strong Q2 Margins, Q3 Guidance Boost Shares, UBS Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGNX\">Cognex</a> (CGNX) posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.</p><p>The company's shares jumped 21% in recent Thursday trading.</p><p>The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance \"firmly above\" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.</p><p>Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.</p><p>UBS has a buy rating on Cognex stock with a price target of $53.</p><p>Price: 40.75, Change: +6.99, Percent Change: +20.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognex's Strong Q2 Margins, Q3 Guidance Boost Shares, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognex's Strong Q2 Margins, Q3 Guidance Boost Shares, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-01 00:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGNX\">Cognex</a> (CGNX) posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.</p><p>The company's shares jumped 21% in recent Thursday trading.</p><p>The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance \"firmly above\" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.</p><p>Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.</p><p>UBS has a buy rating on Cognex stock with a price target of $53.</p><p>Price: 40.75, Change: +6.99, Percent Change: +20.70</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4157","symbol_name":"电子设备和仪器","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2556371868","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556371868","pubTimestamp":1753979581,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cognex  posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.The company's shares jumped 21% in recent Thursday trading.The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance \"firmly above\" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.UBS has a buy rating on Cognex stock with a price target of $53.Price: 40.75, Change: +6.99, Percent Change: +20.70","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4157":"电子设备和仪器","CGNX":"康耐视科技"},"translate_title":"瑞银表示，康耐视第二季度强劲的利润率和第三季度指引提振了股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGNX":1},"content_text":"Cognex (CGNX) posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.The company's shares jumped 21% in recent Thursday trading.The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance \"firmly above\" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.UBS has a buy rating on Cognex stock with a price target of $53.Price: 40.75, Change: +6.99, Percent Change: +20.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}